Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation
Biochemical and Biophysical Research Communications · 2025
DOI: 10.1016/j.bbrc.2025.152008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025. Verfasst von Jing Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 5…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Lignans, Biphenyl Compounds, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Administration of Traditional Chinese Medicine of Jilin Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a rare and highly metastatic form of cancer. Honokiol (HNK), a biphenolic compound, has been utilized in TNBC treatment, though its specific targets remain unclear. This study aimed to elucidate the effects of HNK on TNBC by combining network pharmacology predictions and experimental validation to uncover its mechanisms. MDA-MB 231 and MDA-MB 468 cells were pre-treated with varying doses of HNK for 24 h. Cell viability, proliferation, and apoptosis were assessed using CCK8 and FACS assays, whereas a wound healing assay was used to evaluate cell migration. A tubule formation assay was used to assess blood vessel formation in HUVECs. Additionally, in vivo activity was confirmed using a zebrafish xenograft model. Network pharmacology and molecular docking predicted active ingredients, key targets, and potential mechanisms of HNK against TNBC. Results indicated that HNK induces apoptosis in MDA-MB 231 and MDA-MB 468 cells and inhibits their migration and proliferation. Furthermore, HNK suppressed blood vessel formation. Zebrafish xenograft experiments validated HNK's inhibitory effect on TNBC cells in vivo. Network pharmacology identified 36 potential HNK targets against TNBC, including HSP90AA1, AKT1, EGFR, ERBB2, HSP90AB1, PGR, MDM2, HDAC1, NR3C1, and MAPK14. Key signaling pathways such as PI3K-Akt, MAPK, Rap1, Ras, and FoxO were implicated in HNK's anti-TNBC mechanism. Molecular docking demonstrated spontaneous interactions between HNK and the targeted proteins. In conclusion, HNK may reduce angiogenesis by blocking the EGFR and HSP90AB1 pathways thereby decreasing proliferation and increasing apoptosis in TNBC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China; Medical Research Institute, Guangdong Provincial Key…
- Department of Blood Transfusion, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
- Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
- Department of Gynecology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
- Department of Pharmacy, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
- Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, PR China.
Förderung
- Administration of Traditional Chinese Medicine of Jilin Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Zhang, H., Qiu, M., Hu, J., Lin, L., Mai, L., Huang, G., Chen, X., Li, X., Qin, X., & Zhao, H. (2025). Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.152008
Vancouver
Chen J, Zhang H, Qiu M, Hu J, Lin L, Mai L, et al. Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation. Biochemical and Biophysical Research Communications. 2025. doi:10.1016/j.bbrc.2025.152008
BibTeX
@article{Chen2025,
author = {Chen, Jing and Zhang, Haipeng and Qiu, Min and Hu, Jiemei and Lin, Lu and Mai, Liping and Huang, Guiping and Chen, Xiuyun and Li, Xiaohong and Qin, Xianyu and Zhao, Haishan},
title = {Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
doi = {10.1016/j.bbrc.2025.152008}
}
EUVIMED